Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines

Table 2 The Percentage of Dense-Core Vesicles (DCV) after Treatment with AZ and/or SFN Compare to untreated group in H-727 and H720 xenografts, respectively

Cell type	Treatment	% Reduction of DCV compared to control	* P-value	† P-value
H727	AZ	33 +/− 2.5	p < 0.05	p < 0.01
	SFN	58 +/− 0.8	p < 0.001	p < 0.05
	AZ + SFN	79 +/− 2.3	p < 0.001	-
H720	AZ	24 +/− 1.7	-	p < 0.01
H720	SFN	48 +/− 2.5	-	p < 0.01
	AZ + SFN	70 +/− 1.8	p < 0.01	-

* P-value was measured by comparing treated tumor to an untreated tumor.
† P-value was measured by comparing single agent treatment to a combination treatment.

ISSN: 1471-2407